Phytonanomedicine: a novel avenue to treat recurrent cancer by targeting cancer stem cells.
Journal
Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
03
02
2020
revised:
11
05
2020
accepted:
08
06
2020
pubmed:
20
6
2020
medline:
10
9
2021
entrez:
20
6
2020
Statut:
ppublish
Résumé
Research suggests that tumor relapse and metastasis is caused by minor population of tumor-initiating cells called cancer stem cells (CSCs), which exhibit self-renewability, quiescence, antiapoptosis, and drug resistance. Conventional chemotherapeutics target rapidly proliferating cells but fail to exert cytotoxic effects on CSCs, thus enriching them and driving metastasis and relapse. Hence, targeting CSCs is essential for developing novel therapies for effective cancer treatment. Pertaining to this, several phytochemicals have been identified that exhibit anti-CSC activity. However, poor pharmacokinetics prevents their clinical translation. Hence, developing phytonanomedicine can help to improve the pharmacokinetic profile of these biologically active molecules. In this review, we summarize the current state of the art of phytonanomedicine in the context of CSCs and their clinical status in cancer treatment.
Identifiants
pubmed: 32554061
pii: S1359-6446(20)30228-2
doi: 10.1016/j.drudis.2020.06.003
pii:
doi:
Substances chimiques
Antineoplastic Agents, Phytogenic
0
Phytochemicals
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1307-1321Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.